I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q2, the actual value is USD 591 K.
EPS: As of FY2025 Q2, the actual value is USD -0.16.
Segment Revenue
- Product Revenue: $558,000 for the three months ended June 30, 2025, compared to $584,000 for the same period in 2024, a decrease of 4.5%.
- Service Revenue: $33,000 for the three months ended June 30, 2025, compared to $38,000 for the same period in 2024, a decrease of 13.2%.
Operational Metrics
- Net Loss: $28.8 million for the three months ended June 30, 2025, compared to $23.1 million for the same period in 2024, an increase of 24.8%.
- Gross Profit: $351,000 for the three months ended June 30, 2025, compared to $354,000 for the same period in 2024, a decrease of 0.8%.
- Operating Expenses: $30.5 million for the three months ended June 30, 2025, compared to $26.8 million for the same period in 2024, an increase of 13.7%.
Cash Flow
- Net Cash Used in Operating Activities: $46.4 million for the six months ended June 30, 2025, compared to $41.8 million for the same period in 2024.
- Net Cash Used in Investing Activities: $29.1 million for the six months ended June 30, 2025, compared to $32.6 million for the same period in 2024.
- Net Cash Provided by Financing Activities: $48.4 million for the six months ended June 30, 2025, compared to $0.1 million for the same period in 2024.
Future Outlook and Strategy
- Core Business Focus: The company plans to continue its commercialization efforts for the Platinum line of instruments and invest in research and development for the Proteus platform, which is expected to launch in the second half of 2026.
- Non-Core Business: The company is not currently engaged in significant non-core business activities but is focused on expanding its market presence and product offerings in the proteomics field.